We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and ... Talaris Therapeutics Inc is a late-clinical stage biotechnology company. It is developing transformative cell therapies with the potential to eliminate the burden of chronic immunosuppression for organ transplant recipients as well as induce durable remissions in patients with severe autoimmune and immune-mediated disorders. Show more
– Phase 2 TRANQUILITY trial surpasses enrollment target, with 143 total patients enrolled; topline data expected in second quarter of 2025 – – Deepak L. Bhatt, MD, MPH, MBA and Dipender Gill, MD...
NEW YORK, Nov. 14, 2024 (GLOBE NEWSWIRE) -- Tourmaline Bio, Inc. (Tourmaline) (NASDAQ: TRML), a late-stage clinical biotechnology company developing transformative medicines to dramatically...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.88 | -4.26150121065 | 20.65 | 22.07 | 19.525 | 147087 | 21.28447329 | CS |
4 | -6.625 | -25.0994506535 | 26.395 | 26.59 | 19.14 | 190171 | 22.31608934 | CS |
12 | -6.96 | -26.0381593715 | 26.73 | 29.7883 | 19.14 | 199450 | 25.0089585 | CS |
26 | 6.91 | 53.732503888 | 12.86 | 29.7883 | 12.12 | 196064 | 21.80472662 | CS |
52 | -6.41 | -24.4843391902 | 26.18 | 48.31 | 12.12 | 287298 | 22.96573823 | CS |
156 | 9.45 | 91.5697674419 | 10.32 | 48.31 | 9.18 | 258582 | 22.64522969 | CS |
260 | 9.45 | 91.5697674419 | 10.32 | 48.31 | 9.18 | 258582 | 22.64522969 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions